Anita S. Kablinger, M.D., Ph.D.
Associate Professor of Psychiatry
M.D., 1993, Finch University of Health Sciences / The Chicago Medical School

Major Research Interests:
In the past year research concerning the prodromal period of schizophrenia (the time prior to the onset of psychosis) has been expanding. This is the current area of my research beginning with an article published in October 2000 about “Atypical Antipsychotics and Prodromal Schizophrenia” in the Journal of Nervous and Mental Disease. Our lab has been focusing on biological markers and risk factors for the development of schizophrenia. High-risk groups such as family members of patients with schizophrenia, schizotypal personality disordered patients and first-onset psychosis patients are in the process of evaluation. Family interviews discussing the prodromal period and known risk factors in the patient’s history has been the first step in the study. Then patients and a first-degree relative undergo cognitive testing, MRI and fMRI imaging, and have serum homovanillic acid (pHVA) levels assessed. Our lab also tests for prepulse inhibition (PPI), a measure of sensory gating that is frequently abnormal in patients and relatives with schizophrenia. Eye tracking dysfunction will be the next additional procedure incorporated.

We continue to engage in successful clinical trials, including two NIMH studies in schizophrenia and Alzheimer’s Disease, assessing the differences between the available atypical antipsychotic agents. Trials in anxiety disorders, depression, bipolar disorder and pathological gambling are also ongoing. Other interests pertaining to clinical trials include gender and cultural differences.

Psychopharmacology Research Clinic information

Selected Recent Publications:
Peer-Reviewed:

1. Fitz-Gerald MJ, Kablinger AS: “Model Psychopharmacology Curriculum Comments.” Academic Psychiatry, 25/:2, Summer 2001.

2. Mary Jo Fitz-Gerald, MD, Anita Kablinger, MD, Barbara Manno, Ph.D., O. S. Carter, MD, Gloria Caldito, Ph.D., Stacy Smith, B.A., “Psychiatry Residents’ Participation in Research: A Survey of Attitudes and Experience.” Academic Psychiatry, 2001, Spring, Volume 25, Number 1.

3. Dwyer Donard, Bradley Ronald, Kablinger AS, Freeman AF: “Glucose Metabolism in Relation to Schizophrenia and Antipsychotic Drug Treatment”. ss, Annals of Clinical Psychiatry, Vol. 13, (No. 2) 103-113, 2001.

4. Kablinger AS, Freeman AF: “Prodromal Schizophrenia and Atypical Antipsychotic Treatment.” J Nerv Ment Dis 188(10):642-652, 2000.

5. Rolland P, Kablinger AS, Brannon G, Freeman A: “Treatment of Generalized Anxiety Disorder with Venlafaxine XR: A Randomized, Double-Blind Trial in Comparison with Buspirone and Placebo.” Clinical Trials Investigations, v. 19 (2): 163-165, 2000.

6. Freeman A, Kablinger AS, Rolland Philip, Brannon G: “Millon Multiaxial Personality Patterns Differentiate Depressed and Anxious Outpatients”. Depression and Anxiety 10:73-76, 1999.

7. Kablinger AS, Rolland P, Roggero B, Gary JM, Neu K, Epps W: Recruitment for Clinical Trials: A Psychopharmacology Research Clinic’s Experience in Recruiting for Depression Studies.” The Monitor, v. 13, 1.4 Winter, 1999.

8. Meek JK, Kablinger AS. Antidepressants and posttraumatic stress disorder. Journal of the

Non Peer-Reviewed:

1. Goodman WK, Ward H, Kablinger AS, Murphy T: “Obsessive Compulsive Disorder: Medical Approaches to Treatment-Resistant Cases”. Medscape Mental Health, 1997.

2. Goodman WK, Ward H, Kablinger AS, Murphy T: “Fluvoxamine in the Treatment of Obsessive-Compulsive Disorder and Related Conditions.” Journal of Clinical Psychiatry,1997, 58(Suppl 5):32-49.

Contact Info:
Dr. Anita Kablinger
Associate Professor
Department of Psychiatry
Louisiana State University Health Sciences Center
1501 Kings Highway
Shreveport, LA 71130-3932
318-675-6048
akabli@lsuhsc.edu